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Abstract: Helicobacter pylori (H. pylori) infection triggers a sequence of gastric alterations 
starting with an inflammation of the gastric mucosa that, in some cases, evolves to gastric 
cancer. Efficient vaccination has not been achieved, thus it is essential to find alternative 
therapies, particularly in the nutritional field. The current study evaluated whether curcumin 
could attenuate inflammation of the gastric mucosa due to H. pylori infection. Twenty-eight 
C57BL/6 mice, were inoculated with the H. pylori SS1 strain; ten non-infected mice were 
used as controls. H. pylori infection in live mice was followed-up using a modified 13C-Urea 
Breath Test (13C-UBT) and quantitative real-time polymerase chain reaction (PCR). 
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Histologically confirmed, gastritis was observed in 42% of infected non-treated mice at both 
6 and 18 weeks post-infection. These mice showed an up-regulation of the expression of 
inflammatory cytokines and chemokines, as well as of toll-like receptors (TLRs) and 
MyD88, at both time points. Treatment with curcumin decreased the expression of all these 
mediators. No inflammation was observed by histology in this group. Curcumin treatment 
exerted a significant anti-inflammatory effect in H. pylori-infected mucosa, pointing to the 
promising role of a nutritional approach in the prevention of H. pylori induced deleterious 
inflammation while the eradication or prevention of colonization by effective vaccine is  
not available. 
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1. Introduction 
Helicobacter pylori (H. pylori) is one of the most common human pathogens since it infects the gastric 
mucosa of about 50% of the world’s population [1]. The majority of infections are asymptomatic, 
acquired by an overwhelming majority of the pediatric population, making the infection life-long without 
effective bacterial eradication. Additionally, epidemiological studies associating the infection with a 
higher risk of gastric malignancy lead the World Health Organization for Research in Cancer to classify 
H. pylori as a class I carcinogen [2]. H. pylori infection is a major risk factor for gastric cancer 
development because it triggers a stepwise sequence in the gastric mucosa starting with superficial 
gastritis, which can progress to chronic gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and, 
ultimately, gastric carcinoma [3]. The bacteria induce a host immune response (innate and adaptative), 
but the persistence of the infection suggests that the response is not effective in eliminating the infection. 
Furthermore multiple lines of evidence suggest that the immune response contributes to the pathogenesis 
associated with the infection. 
Over the last two decades, several experimental models of H. pylori infection have been developed 
to investigate the pathogenesis of this infection. Using a mouse-adapted H. pylori strain (Sidney Strain, 
SS1), Lee et al. established a model of long-term and high bacterial colonization in mice [4]. Although 
H. pylori is known to be non-invasive, an extensive inflammatory reaction is provoked in the gastric 
mucosa as a consequence of the infection [5]. This reaction is characterized by a mucosal infiltration of 
inflammatory cells, especially neutrophils, which is mediated by enhanced expression of proinflammatory 
chemokines and cytokines [6,7]. 
Given the high prevalence of H. pylori infection worldwide, the high costs of antibiotic treatment, 
and the increasing rates of antibiotic resistance, considerable efforts have been made to develop vaccines 
against H. pylori. However, efficient vaccination has not been achieved in human beings to date [8]. 
Thus it is essential to find alternative therapies, particularly related to nutrition, such as plant extracts 
that contain numerous polyphenols, which have been shown to reduce inflammation [9]. Curcumin, a 
naturally occurring phytochemical and an extract of Curcuma longa (turmeric), is known to possess 
many pharmacologic properties and is widely used in herbal medicine, such as for peptic diseases in 
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ayurvedic medicine [10]. Moreover, curcumin has proven to exhibit remarkable anticarcinogenic,  
anti-inflammatory, and antioxidant properties [11,12]. 
Thus, curcumin may be a potential agent for controlling inflammation associated with H. pylori 
infection. The aim of the present study is to evaluate the anti-inflammatory effect of curcumin using the 
experimental model of H. pylori chronic infection. 
2. Experimental Section 
2.1. Experimental Infections 
A total of 38 pathogen-free male C57BL/6 5-week-old mice (Harlan Laboratories, Castellar,  
Spain—Genetic code: C57BL/6JOla-Hsd) were used in compliance with the national animal guidelines. 
The present study was specifically approved by the National Animal Care Committee from the Portuguese 
General Veterinary Direction. 
The animal facility had a regulated room temperature (21 °C–24 °C), humidity (55% ± 10%), and an 
artificial standard 12-h light/12-h dark cycle. 
All mice had ad libitum access to tap water and feeding (standard diet—Mmucedola srl-Italy-4RF21 
certificate batch: 250202) and were kept in standard mice plastic cages (size 13 cm high, 30 cm length 
and 20 cm wide) with a Souralit 3000 beeding (batch: 118/11 with no pre-treatment). 
After an acclimatization period of two weeks, the mice were divided into three different  
groups: Control group (CG), n = 10, Infected group (IG), n = 14, Infected group treated with Curcumin 
(IG + C), n = 14. Using a 20-gauge ballpoint metal feeding tube (Harvard Apparatus, Inc., Holliston, 
MA, USA), mice were inoculated intragastrically, on three consecutive days, with either 0.1 mL of  
H. pylori SS1 cell suspension containing 108 colony-forming units/mL (IG and IG + C) or phosphate 
buffered saline (PBS) (CG). Two weeks after infection, the IG + C group received 0.5 mL of a lipidic 
solution of curcumin (Sigma-Aldrich, Sintra, Portugal) (500 mg/kg) [13,14], and the IG received PBS; 
both regimens were given three times a week, for 6 and 18 weeks by gavage. 
At Week 6, the five non-infected mice (CG) and seven mice from both the IG and IG + C groups, 
were killed. The remaining mice of each group were killed at Week 18. 
The mice were food-deprived for 14 h prior to euthanization by cervical dislocation. For each mouse, 
half of the stomach was totally processed for histology and immunohistochemistry, and the remaining 
half was split in two, one part was immediately conserved at −80 °C in RTL buffer (Qiagen GmbH, 
Hilden, Germany) with 2-mercaptoethanol (Sigma-Aldrich, Sintra, Portugal) for RNA extraction, and the 
remaining half was used for DNA extraction. 
2.2. Urea Breath Test (13C-UBT) and Quantitative Real-Time PCR (qPCR) for H. Pylori 
The presence or absence of active H. pylori infection was evaluated for all mice one week after the 
infection, and again at both 6 and 18 weeks after infection, before euthanasia, with an adapted  
13C-UBT, as previously described [15]. 
A qPCR was performed on extracted DNA from the stomach in order to evaluate the putative effect 
of curcumin treatment on H. pylori.  
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A real-time PCR based on SYBR Green technology was used to quantify H. pylori and mouse 
GAPDH (Glyceraldhehyde 3-phosphate deshydrogenase), an epithelial cell target, in stomach DNA 
extracts. H. pylori specific PCR targets the gene encoding 23S rRNA of H. pylori as already  
described [16]. GAPDH primers (mGapdh1for: CTGCAGGTTCTCCACACCTATG; mGapdh1rev: 
GAATTTGCCGTGAGTGGAGTC) were designed using Primer Express software (Life Technologies). 
Each sample was tested twice for 23S rRNA and GAPDH (Eurofins, Luxembourg, Luxembourg). 
Two standard ranges were prepared, the first one with DNA extract from bacterial calibrated 
suspension (UFC/mL) of H. pylori SS1 strain, the second with DNA from murine epithelial cells  
(m-Iccl2 line) [17] at a known concentration. Two standard curves were obtained and used to quantify 
the number of bacteria and murine cells, respectively, by μL of DNA. Final results were expressed by 
the ratio bacteria/μL of DNA on murine cells/μL of DNA. 
LightCycler(r) 480 SYBR(r) Green I Master Mix (Roche Diagnotics reagent was used according to 
supplier’s recommendations. PCR were performed on Light cycler 480 (Roche Diagnostics, Bâle, 
Switzerland). Following initial denaturation at 95 °C for 10 min, 45 amplification cycles (95 °C for  
10 s, 60 °C for 10 s, and 72 °C for 15 s) were performed. Fluorescence was measured at 640 nm after 
each cycle. This was followed by a melting program of 95 °C for 60 s and 38 °C for 50 s at a temperature 
transition rate of 20 °C/s and 90 °C for 0 s (hold time) at a rate of 0.1 °C/s, with continuous monitoring 
of the fluorescence. The final step consisted of cooling at 2.2 °C/s to 40 °C. The results are presented as 
the ratio 23S rRNA/GAPDH. 
2.3. Immunohistochemistry and Histology 
Sections of buffered formalin-fixed paraffin-embedded tissue blocks (2 μm thick) were cut onto 
Superfrost plus slides. After baking in an oven, the 2 μm sections were de-waxed, rehydrated, and 
subjected to epitope antigen retrieval (20 min, 94 °C) with Target Retrieval Solution High pH  
50× EnvisionTM Flex (Dako, Glostrup, Denmark) in a pre-treatment module PTlink (Dako). 
Endogenous peroxidase was blocked with 2% H2O2 in absolute methanol for 10 min. Immunostaining 
was performed by the peroxidase-indirect-polymer method. Primary polyclonal rabbit  
anti-Helicobacter Pylori (Dako, Glostrup, Denmark), was incubated for 30 minutes at room temperature. 
The labeled polymer HRP anti-rabbit (Dako EnVisionTM, Carpinteria, USA) detection staining system 
was used at room temperature for 30 minutes and DAB (3,3′-diaminobenzidine) for visualization. 
Sections were counterstained with Mayer’s Hematoxylin. As positive control a mouse gastric specimen 
previously known to be positive was used for HP. For negative control, primary antibody was omitted 
during the staining. 
For histological analysis, mouse stomach samples were fixed with 10% buffered formalin solution,  
pH 7.0, routinely processed, and embedded in paraffin. Sections of tissue blocks 4 μm thick were cut 
onto glass slides and stained with hematoxylin-eosin (H & E). Inflammation was blindly observed and 
graded from zero to three as described elsewhere [18]. 
2.4. Real-Time PCR Arrays 
For PCR arrays, three mice from each group, CG, IG, and IG + C, at all time-points of the experiment, 
were randomly chosen and tested individually. Total RNA from mouse stomach samples was extracted 
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using the RNeasy Mini kit (Qiagen GMbH, Hilden, Germany), including the DNase I digestion step to 
eliminate residual genomic DNA, as recommended by the manufacturer. Integrity and concentration of each 
RNA sample was analyzed in the Agilent 2100 Bioanalyzer. Then 500 ng of RNA were reverse transcribed 
to single-stranded cDNA using the RT2 First Strand kit (Qiagen) according to manufacturers’ protocols. 
Analysis of expression of 84 inflammation mediator genes, as well as of five housekeeping genes 
(HKG), was performed by PCR array, using the RT2 Profiler PCR Array mouse inflammatory response 
and immunity pathway (SABioscience, Qiagen), in a 384-well format, using the Applied Biosystems 
7900HT Fast Real-Time PCR System. Data was normalized to the mean values of the five HKG, and 
the relative amount of RNA was calculated using the 2−ΔCt method. 
Fold-change calculations were done using SABiosciences’ data analysis software, which 
automatically calculates the fold-change in gene expression between the infected non-treated mice and 
the control group (IG versus CG), and between the infected and curcumin treated mice and the control 
group (IG + C versus CG). Fold-change values greater than one indicate an up-regulation, while  
fold-changes less than one indicate a down-regulation. 
2.5. Statistical Analysis 
Differences on the histology score were tested by the Mann-Whitney U test. Student’s t test was used 
for the remaining statistics. Both tests were considered as statistically significant when p < 0.05. Results 
are expressed as averages ± standard deviation (SD) of n observations. 
3. Results 
3.1. H. Pylori Status 
At all the time points analyzed, 1 week, 6 and 18 weeks after the infection, H. pylori was detected in 
all the 28 inoculated mice, both by 13C-UBT (Supplementary Figure S1) and by immunohistochemistry 
(Figure 1A), independent of treatment with curcumin. 
Mice from the CG were all negative for H. pylori infection. Interestingly, from week 1 to week 18, a 
non-significant reduction in the 13CO2 values assessed by 13C-UBT was observed for all the infected 
mice. These results were confirmed by qPCR, for which no H. pylori DNA was detected among the non-
infected mice, while no difference in H. pylori DNA content was observed between infected mice at 6 
and 18 weeks, either treated or non-treated with curcumin (Figure 2). 
3.2. Histology 
The inflammation of gastric mucosa was analyzed without previous knowledge by the observer. For 
the CG mice, no inflammation of gastric mucosa was observed at either point in time. Among the 
infected mice, three of seven (42.8%) presented moderate inflammation (Score 2) at Week 6, and mild 
inflammation (Score 1) was also observed in three out of seven mice (42.8%) at 18 weeks  
(Figure 1B,C and Supplementary Table S1). No inflammation of gastric mucosa was observed in the 
curcumin-treated mice at either 6 or 18 weeks post-infection (Figure 1D). Differences among infected 
treated and non-treated groups were statistically significant for the 6 weeks of infection (U = 3.5,  
p = 0.004), but not for the 18 weeks of infection (U = 14.0, p = 0.209) (Supplementary Table S1). 
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Figure 1. Gastric mucosa of an infected mouse. Immunohistochemistry for H. pylori, 40× 
(black arrows indicate bacteria) (A). Mucosal inflammation at 6 (B) and 18 weeks (C) of the 
infected non-treated mice (hematoxylin & Eosin (H & E) × 10). Black arrows indicate small 
lymphoid aggregates at the mucosa (B) and a well-defined lymphoyid aggregate at the 
submucosa (C)—Normal gastric mucosa (H & E × 10) of infected mice treated with 
curcumin at 18 weeks (D). 
 
Figure 2. Quantitative real-time polymerase chain reaction (PCR) evaluating the load of  
H. pylori in the mouse gastric mucosa. Values denote the means of the ratio  
23S rRNA/GAPDH, obtained for each of the mice analyzed in each group, each mouse tested 
in duplicate. 6W and 18W, refer to the groups of infected mice at 6 and 18 weeks, 
respectively; Curc_6W and Curc_18W, refer to the groups of infected mice, receiving 
treatment with curcumin, at 6 and 18 weeks, respectively. 
3.3. Real-Time PCR Arrays 
Of the 84 mouse inflammatory response and immunity pathway genes analyzed, 69 showed at least 
a three-fold difference in gene expression between normal mice (CG) and the infected non-treated mice 
(IG). At week 6, up-regulation was observed in 64 genes, while five genes appeared to be down-regulated 
in the infected mice, (Figure 3A and Supplementary Table S2). At week 18, up-regulation was observed 
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in 78 genes, and only two genes appeared to be down-regulated in the infected mice (Figure 3B and 
Supplementary Table S2). 
A: 6 weeks post-infection, non-treated mice (n = 3) 
 
B: 18 weeks post-infection, non-treated mice (n = 3) 
 
C: 6 weeks post-infection, curcumin-treated mice (n = 3) 
 
D: 8 weeks post-infection, curcumin-treated mice (n = 3) 
 
Figure 3. Relative expression level (2−ΔCt) for the 84 mouse inflammatory response and 
immunity encoding genes, between normal mice and Helicobacter pylori-infected mice at 
Week 6 post-infection (A) and at Week 18 post-infection (B); and between normal mice and 
Helicobacter pylori-infected mice treated with curcumin at Week 6 post-infection (C) and 
at Week 18 post-infection (D). Values denote the means obtained for each of the mice 
analyzed in each group, each mouse tested in duplicate (± SD). The grey lines indicate a 
three-fold change in gene expression threshold. 
The treatment of mice with curcumin for 6 and 18 weeks down-regulates the expression of almost all 
studied genes. This effect was more pronounced at 6 weeks of treatment than at 18 weeks (Figure 3C,D 
and Supplementary Table S2). The pro-inflammatory cytokines and receptors were included in the group 
of up-regulated genes, at Week 6, among which were the main genes involved in the immune response 
against H. pylori infection: IL-1β, IL-6, IL-9, IL-10, IL-23a, IFN-γ, TNF-α, and Fasl (range of fold-change 
between infected and non-infected mice varied from 23.9 to 1338.6) (Figure 4A). 
The same scenario was observed for the chemokines, with special emphasis on CCl2, CCL20, CCL25, 
CxCL1, CxCL2, and CxCL11, with fold-change ranging from 22.7 to 717.5 (Figure 4B). 
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Figure 4. Fold-change in expression of mouse inflammatory response and immunity 
encoding genes, as determined by PCR arrays and calculated using the 2−ΔCt method, 
comparing the Helicobacter pylori-infected non-treated mice and the infected and treated with 
curcumin mice versus non-infected mice, at Week 6 post-infection and at Week 18  
post-infection: (A) mouse cytokines; (B) mouse chemokines; (C) mouse toll-like receptors 
(TLR) and MyD88. Values denote the means obtained for each of the mice analyzed in each 
group, each mouse was tested in duplicate (± SD). p < 0.05 for all the comparisons between 
the infected non-treated and the infected curcumin treated groups except for IFN-γ at Week 
18. Values denote the means obtained for each of the three mice analyzed in each group, 
each mouse was tested in duplicate (± SD). 
Among the toll-like receptors (TLRs), the genes encoding for TLR1, TLR5, TLR6, and TLR7 showed 
the largest increase range in the infected mice (range of fold-change from 6 to 1123), as well as the 
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universal adapter protein MyD88 (fold-change of 83.3), which is used by almost all TLRs to activate the 
transcription factor nuclear factor kappa beta (NF-κB) (Figure 4C). 
At week 18, up-regulation of the genes was even more pronounced, with fold-change ranging between 
400.4 and 8251.1 for the main pro-inflammatory cytokines (Figure 4A), and between 135.5 and 1191.9 
for chemokines (Figure 4B). Regarding the TLRs, a marked up-regulation was also observed, with  
fold-change ranging from 99.2 to 6164.5, and a fold-change of 446.3 for the MyD88 encoding gene 
(Figure 4C). 
An increased in expression of the inducible nitric oxide synthetase (iNOS) was also observed for the 
infected non-treated mice compared to the control group, at both Week 6 (fold-change of 224) and Week 
18 (fold-change of 2161). 
Treatment of infected mice with curcumin drastically decreased the expression of all the 
inflammatory mediators, restoring their levels to those similar to the non-infected mice (Figure 3C,D). 
Indeed, at Week 6, among the 84 inflammatory response and immunity pathway tested genes, only  
18 genes were still more expressed in the treated group than in the control group, with fold-changes 
varying from 3.2 to 9.0. In comparison with the infected non-treated mice, the levels of fold-change in 
gene expression for the curcumin-treated mice were significantly lower, averaging 100 times less for the 
cytokines, 70 times less for the chemokines’ group, and 230 times less for the TLRs and MyD88 
encoding genes (Figure 4A–C). 
At Week 18, 65 out of the 84 genes tested in the curcumin-treated mice were still up-regulated 
compared to the control group; however the levels of fold-change decreased on average five times when 
compared to the fold-change observed in the infected non-treated mice (Figure 4A–C). For each gene 
category the effect of curcumin on the infected mice, compared to the infected non-treated group, was 
as follows: eleven times decrease in fold-change for the cytokines, seven times for chemokines, and ten 
times for TLRs and MyD88. 
Overall, the effect of curcumin on inflammation due to H. pylori infection was more pronounced after 
6 weeks of infection than after 18 weeks, even if, in this case, the treatment was more prolonged. 
Curcumin had a pronounced effect on all inflammatory mediators’ encoding genes, with special 
emphasis on cytokines, chemokines, and TLRs. 
4. Discussion 
This study focused on the evaluation of the anti-inflammatory properties of curcumin by both 
histological and molecular approaches, in the context of the chronic infection by H. pylori, using the  
in vivo mouse model. 
Our data confirm that the mouse-adapted H. pylori SS1 strain is well adapted to the mouse stomach 
milieu, which explains the high infection rate (100%) achieved in this study, even after 18 weeks of 
infection. Despite the low number of tested mice, the histological analysis performed showed that 
curcumin was effective in reducing the inflammation of the gastric mucosa of H. pylori-infected mice, 
which was confirmed at the molecular level. At this level the magnitude of the difference in the 
expression of the inflammatory mediators’ encoding genes between the infected curcumin-treated mice 
and the infected but non-treated ones strongly supports the powerful anti-inflammatory properties  
of curcumin. 
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Inhibition of H. pylori growth was unlikely to be a mechanism that contributed to the effect of 
curcumin observed in this study, since positive results regarding the presence of bacteria were still 
obtained from both 13C-UBT and qPCR. Although the amount of recovered 13CO2 from breath analysis 
of all infected groups slightly decreased with time during the experiment, it was not significantly 
different between the groups at all time points, which was corroborated by the qPCR results. Moreover, 
the H. pylori colonization density measured by immunohistochemistry showed a positive result in all 
mice including the treated ones. 
One can speculate that curcumin, although not bactericidal, may affect the expression/amounts of 
virulent genes. 
Recently, Sintara et al. [19] in rats using histology and Di Mario et al. [20] in humans, using serology, 
demonstrated that treatment with curcumin significantly improved gastric inflammation associated with 
H. pylori infection despite persistence of the bacterium, supporting the findings of this study. However, 
these data are not confirmed by Kundu et al. [21] who suggested that curcumin acted two ways during 
protection against H. pylori infection, i.e. by eradicating H. pylori as well as potentially targeting key 
molecules involved in the H. pylori-induced gastric diseases. 
According to Goel et al. [22], eradication by curcumin may be dependent on a high dose of this 
chemopreventive agent, the safety of which still has to be confirmed in animals and humans. 
There are two main mechanisms by which H. pylori (or its products) may produce gastric 
inflammation. Firstly, the organism may interact with surface epithelial cells, producing either direct cell 
damage or the liberation of epithelial-derived pro-inflammatory mediators (chemokines). The epithelial 
chemokine response may be particularly important in the early stages of H. pylori-induced inflammation, 
with the epithelium acting as a crucial first line of defense against microbial infection. Secondly,  
H. pylori-derived products may gain access to the underlying mucosa, thereby directly stimulating host 
non-specific and specific immune responses involving the liberation of a variety of cytokine messengers [23]. 
Our data clearly show an increased expression of a set of chemokines (CCL20, CCL5, CXCL1, 
CXCL10, CXCL11, CCL25) normally involved in H. pylori gastritis [24–26] at both 6 and 18 weeks of 
infection in mice, which decreased after curcumin treatment. 
Still in the context of non-specific (innate) immunity, the literature describes an increase in the 
secretion of TNF-α, IL-6, and IL-1β during H. pylori infection, with all three polypeptides being 
predominantly macrophage-derived cytokines with a wide range of pro-inflammatory actions involved 
in leukocyte recruitment and activation [27,28]. Our study confirmed these data, showing a marked 
increase in the expression of these cytokines in the infected mice, which decreased significantly after 
treatment with curcumin. 
Innate immune activation depends on the input of multiple microbial stimuli. Similar to other bacteria, 
H. pylori activates several TLRs on epithelial and dendritic cells (DCs). It is possible that different TLRs 
ligands derived from the same microbe induce distinct and opposite effects on DCs [29–31]. To date, 
eleven members of the TLRs family have been found to be expressed in mice [32]. TLRs are key 
molecules mediating the interaction between H. pylori and DCs, which is largely dependent on the 
adaptor protein MyD88 signaling that is used by all TLRs except TLR3 [8]. Our data are consistent with 
the ones mentioned above, showing a significant increase in MyD88 expression in infected mice, as well 
as of several TLRs [33]. Once again, treatment of infected mice with curcumin restored the normal range 
of all these molecules. 
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With regard to adaptive immunity, the discovery of Th17 cells was a major step in our understanding 
of CD4 + T cell responses to H. pylori infection. The early events in the immune response of immunized 
and challenged mice include the recruitment of T cells. In murine systems, Th17 cell differentiation 
depends on the presence of IL-6, transforming growth factor beta (TGF-β1), and CCL20, which are 
significantly increased in H. pylori-stimulated macrophages. Subsequently, IL-23 that is increased in 
patients with H. pylori gastritis will promote Th17 cell proliferation via the STAT3 pathway [33,34]. 
The NF-κB pathway participates in the production of these inflammatory mediators in response to  
H. pylori [35]. In a similar way to that found with the previously described chemokines, the expression 
of this set of cytokines was also increased in our infected mice (TGF-β was not measured) and decreased 
significantly after treatment with curcumin. It is worth noting that gastric epithelial cells stimulated by 
IL-17 also lead to production of chemokines, including CCL25, chemotactic factor for macrophages, 
activated monocytes, and DCs. In our study, we found an increase in the expression of this cytokine, 
probably reflecting IL-17 stimulation, the level of which returned to normal after curcumin therapy. 
Shi et al. [36] suggest that H. pylori infection induces a mixed Th17/Th1 cell response and the 
Th17/IL-17 pathway modulates Th1 cell responses and contributes to pathology. It is generally accepted 
that H. pylori infection results in a Th1-dominant response and gastric inflammation that depends on 
Th1 cells is characterized by the production of IFN-γ [37–40]. Accordingly, the infected mice in this 
study showed a strong Th1 response, with high expression of IFN-γ at both 6 and 18 weeks after 
infection, which regressed after treatment with curcumin mainly at Week 6 post-infection. 
We may wonder what the rational for the beneficial effects of curcumin is in the context of gastric 
infection by H. pylori. The pathogenesis of this infection is associated with bacterial virulence factors 
that can induce the activation of NF-κB in gastric epithelial cells [19,41]. This transcription factor is an 
important regulator of many cellular processes, including the control of immune response and 
inflammation [42,43]. For example, the NF-κB pathway participates in the production of inflammatory 
mediators in H. pylori-stimulated macrophages critical for differentiation and proliferation of Th17  
cells [35]. Curcumin has many biological attributes, including anti-inflammatory properties [19],  
and most of these effects can be explained by the efficient inhibition of NF-κB mediated by this 
substance [44–46]. Previous studies have shown that curcumin can inhibit NF-κB activation in  
H. pylori-infected gastric epithelial cells [47], as well as in rats [48]. In this last study, H. pylori-induced 
gastric inflammation was associated with increased NF-κB activation and macromolecular leakage, 
which was reduced by curcumin supplementation. In our study the quantification of NF-κB by an 
alternative method (like qPCR or immunohistochemistry) was not performed, which is a clear limitation 
of the study. Identifying the localization of NF-κB in the gastric mucosa by immunohistochemistry, if 
performed, would also have been of informative relevance. 
Another point that deserves attention is the observation that despite curcumin fully abolishing the 
gastric mucosa inflammation, a total remission of gene expression of inflammation markers was not 
observed. In our study, we also observed a discrepancy between histological inflammatory scores and 
inflammatory genes by PCR arrays for all infected mice, before or after curcumin treatment, and the 
more pronounced gene expression observed at Week 18 post-infection in the non-treated mice had no 
parallelism in higher histological inflammation scores, compared to Week 6 post-infection. One possible 
explanation for this is the fact that some adaptive host factors may also contribute to mucosal protection. 
Considering the limited number of mice in each group and that we did not observe a consistent exuberant 
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mucosal inflammation for any mouse at any time of the experiment, it can be speculated that mouse 
infection with the human pathogen H. pylori might not be the ideal model of inflammation, at least 
regarding histological parameters. 
5. Conclusions 
In conclusion, as far as we know, this is one of the few studies using both histological and molecular 
approaches, showing the important anti-inflammatory role of curcumin in the context of chronic  
H. pylori infection. Taking into account the extensive consumption of polyphenols in the human diet 
(curcumin and others), our data points to the promising role of a nutritional approach in the control of 
H. pylori induced deleterious inflammation while an effective vaccine is not available. 
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